Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04278131
PHASE1/PHASE2

BS01 in Patients With Retinitis Pigmentosa

Sponsor: Bionic Sight LLC

View on ClinicalTrials.gov

Summary

A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa

Official title: Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2020-02-06

Completion Date

2029-12-30

Last Updated

2026-01-23

Healthy Volunteers

No

Interventions

DRUG

BS01

Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)

Locations (1)

New Jersey Retina

Teaneck, New Jersey, United States